Crohn Disease
774
142
184
279
Key Insights
Highlights
Success Rate
79% trial completion
Published Results
75 trials with published results (10%)
Research Maturity
279 completed trials (36% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
9.8%
76 terminated out of 774 trials
78.6%
-8.0% vs benchmark
15%
114 trials in Phase 3/4
27%
75 of 279 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 279 completed trials
Clinical Trials (774)
A Long-term Extension Study of Ustekinumab in Pediatric Participants
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
A Study of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
STUDY OF THE ADDED VALUE OF A TRANSMURAL EVALUATION IN PATIENTS WITH CROHN'S DISEASE UNDER BIOTHERAPY WITH CLOSE FECAL CALPROTECTIN FOLLOW-UP
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Low Dose IL-2 for the Treatment of Crohn's Disease
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
The CROCO Study: CROhn's Disease COhort Study
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
Autologous Stem Cells in the Management of Fistulating Perianal Crohn's Disease
A Specific Probiotic in thE MOdulation of Gut Microbiota of patieNts With Mild-to-modErate Ulcerative Colitis
Autologous Stem Cell Transplant for Crohn's Disease
Developing a Self-Management Intervention to Improve Health Outcomes for Patients With Inflammatory Bowel Disease
A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)
Cranberry and Gut Health in Crohn's Disease